MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Harvard Bioscience Inc

Открыт

СекторЗдравоохранение

0.59 5.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.56

Макс.

0.59

Ключевые показатели

By Trading Economics

Доход

1.1M

-1.2M

Продажи

141K

21M

Рентабельность продаж

-5.978

Сотрудники

330

EBITDA

1M

1.2M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+244.83% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

11 мар. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

616K

26M

Предыдущая цена открытия

-4.77

Предыдущая цена закрытия

0.59

Новостные настроения

By Acuity

26%

74%

71 / 360 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Harvard Bioscience Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

21 янв. 2026 г., 23:49 UTC

Главные движущие силы рынка

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 янв. 2026 г., 21:12 UTC

Главные движущие силы рынка

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 янв. 2026 г., 21:00 UTC

Приобретения, слияния, поглощения

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 янв. 2026 г., 20:29 UTC

Главные движущие силы рынка

Chip Makers Gain After Trump Calls Off European Tariffs

21 янв. 2026 г., 20:04 UTC

Главные движущие силы рынка

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 янв. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 янв. 2026 г., 23:34 UTC

Обсуждения рынка

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 янв. 2026 г., 22:39 UTC

Отчет

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

21 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

21 янв. 2026 г., 21:35 UTC

Приобретения, слияния, поглощения

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 янв. 2026 г., 21:19 UTC

Отчет

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 янв. 2026 г., 20:45 UTC

Приобретения, слияния, поглощения

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 янв. 2026 г., 20:36 UTC

Обсуждения рынка

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 янв. 2026 г., 20:31 UTC

Обсуждения рынка

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 янв. 2026 г., 20:27 UTC

Приобретения, слияния, поглощения

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 янв. 2026 г., 20:27 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

21 янв. 2026 г., 20:27 UTC

Обсуждения рынка

Was It a 'TACO' Event? -- Market Talk

21 янв. 2026 г., 20:26 UTC

Приобретения, слияния, поглощения

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 янв. 2026 г., 20:23 UTC

Приобретения, слияния, поглощения

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 янв. 2026 г., 20:21 UTC

Приобретения, слияния, поглощения

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 янв. 2026 г., 20:19 UTC

Приобретения, слияния, поглощения

Deutsche Boerse Group Agrees to Buy Allfunds

21 янв. 2026 г., 20:08 UTC

Отчет

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 янв. 2026 г., 20:03 UTC

Обсуждения рынка

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 янв. 2026 г., 19:51 UTC

Обсуждения рынка

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 янв. 2026 г., 19:43 UTC

Обсуждения рынка

U.S. Ethanol Production Expected to Slip -- Market Talk

21 янв. 2026 г., 19:31 UTC

Обсуждения рынка

Gold Settles at Fresh All-Time High -- Market Talk

21 янв. 2026 г., 19:24 UTC

Отчет

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 янв. 2026 г., 19:10 UTC

Обсуждения рынка

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 янв. 2026 г., 18:57 UTC

Обсуждения рынка

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Сравнение c конкурентами

Изменение цены

Harvard Bioscience Inc Прогноз

Целевая цена

By TipRanks

244.83% рост

Прогноз на 12 месяцев

Средняя 2 USD  244.83%

Максимум 2 USD

Минимум 2 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Harvard Bioscience Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

1

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.3 / 0.3401Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

No Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

71 / 360Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat